There are currently 1502 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: Parkland Memorial Hospital, Dallas, Texas +1 locations
Conditions: Ovarian Carcinoma
Register for Updates
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT03013998
Recruiting
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negativ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Register for Updates
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT02064673
Recruiting
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Gender:
MALE
Ages:
Between 30 years and 80 years
Trial Updated:
09/16/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
NCT05267262
Recruiting
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Gender:
ALL
Ages:
12 years and above
Trial Updated:
09/16/2024
Locations: Investigative Site, Dallas, Texas
Conditions: Alport Syndrome, Focal Segmental Glomerulosclerosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.
NCT06493578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/16/2024
Locations: Dermatology Treatment and Research Center, Dallas, Texas
Conditions: Non-segmental Vitiligo
Register for Updates
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Register for Updates
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239
Recruiting
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/13/2024
Locations: Recognify Research Site, Dallas, Texas
Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Register for Updates
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
NCT05900986
Recruiting
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed fr... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
09/11/2024
Locations: Integro Theranostics Research Site #3, Dallas, Texas
Conditions: Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Register for Updates
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
NCT04588922
Recruiting
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractor... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
09/11/2024
Locations: Baylor Scott & White Health, Dallas, Texas
Conditions: Hematologic Malignancies
Register for Updates
Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
NCT06394570
Recruiting
STAR-EV will evaluate the combination of enfortumab vedotin plus radiotherapy (RT) as neoadjuvant treatment for muscle invasive bladder cancer prior to radical cystectomy surgery. The study will use "dose escalation" to evaluate the safety and efficacy of study treatment at three dose regimens: Level 0: EV treatment followed by RT to the bladder Level 1: EV treatment with RT starting on Cycle 2, Day 15 Level 2: EV treatment with RT starting on Cycle 1, Day 15 Following completion of EV+RT neoa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Bladder Cancer
Register for Updates
Polypill for Prevention of Cardiomyopathy
NCT06143566
Recruiting
This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or usual care. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypo... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/09/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Type 2 Diabetes, High Blood Pressure
Register for Updates
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer
NCT03546686
Recruiting
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after taxane-based neoadjuvant chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Breast Cancer
Register for Updates